此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

ICat2,GAIN(基因组评估为新疗法提供信息)联盟研究

2026年9月17日 更新者:Katherine A. Janeway, MD、Dana-Farber Cancer Institute

在患有实体瘤的儿童和年轻人中接受与个性化癌症治疗 (iCat) 建议相匹配的靶向治疗后评估结果的多中心队列研究:iCat2,GAIN 联盟研究

This research study is evaluating the use of specialized testing of solid tumors including sequencing. The process of performing these specialized tests is called tumor profiling. The tumor profiling may result in identifying changes in genes of the tumor that indicate that a particular therapy may have activity. This is called an individualized cancer therapy (iCat) recommendation. The results of the tumor profiling and, if applicable, the iCat recommendation will be returned.

研究概览

地位

主动,不招人

详细说明

Patients with extra-cranial (not in the brain) solid tumors that are either difficult to diagnose or more difficult to treat are eligible to participate in this study. All enrolled patients will have targeted sequencing of tumor performed. Sequencing results will be reviewed for clinically significant findings including determination of whether any mutations exist that suggest potential for activity of a targeted therapy (iCat recommendation). Results will be returned to the patient's oncologist and follow-up data will be collected.

In this prospective multi-center cohort study, the primary objective is to describe the outcomes of pediatric patients with advanced solid tumors according to whether or not they received of targeted therapy matched to an iCat recommendation. The primary clinical outcome of interest is the endpoint of overall survival (OS), with progression-free survival and response rate (RR) as key secondary clinical outcome measures. To address this hypothesis, 825 patients will enroll from an anticipated 11 participating institutions over 3 years.

研究类型

观察性的

注册 (估计的)

825

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • San Francisco、California、美国、94158
        • University of California San Francisco
    • Colorado
      • Aurora、Colorado、美国、80045
        • Children's Hospital Colorado
    • District of Columbia
      • Washington D.C.、District of Columbia、美国、20010
        • Children's National Medical Center
    • Illinois
      • Chicago、Illinois、美国、60637
        • University of Chicago Comer Children's Hospital
    • Massachusetts
      • Boston、Massachusetts、美国、02215
        • Dana-Farber Cancer Institute
      • Boston、Massachusetts、美国、02215
        • Boston Children's Hospital
    • New York
      • New York、New York、美国、10032
        • Columbia University Medical Center
    • Ohio
      • Columbus、Ohio、美国、43205
        • Nationwide Children's Hospital
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • Children's Hospital of Philadelphia
    • Texas
      • Dallas、Texas、美国、75390
        • University of Texas Southwestern Medical Center at Dallas
    • Utah
      • Salt Lake City、Utah、美国、84113
        • University of Utah Childrens Medical Center
    • Washington
      • Seattle、Washington、美国、98105
        • Seattle Children's Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

不超过 30年 (孩子、成人)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

High-risk, relapsed and refractory solid tumors

描述

Inclusion Criteria:

  • Age -- Age ≤ 30 years at time of initial qualifying solid tumor diagnosis

  • Diagnosis -- Histologic diagnosis of solid malignancy (excluding brain tumors and lymphoma) that meets at least one of the following criteria:

    • Refractory, defined as tumor progression after initiation of standard first line therapy without having achieved a prior partial or complete remission OR Biopsy proven residual disease at the completion of planned standard initial front-line therapy.
    • Recurrent, defined as tumor progression after achieving a prior partial or complete remission
    • Newly diagnosed high risk disease, defined as having an expected event free survival of < 50% at 2 years.
    • Lacks definitive diagnosis or classical genomic findings after histologic review and standard molecular testing (rare tumor group).
  • Examples include (eligibility not limited to these examples):

  • Histology typically associated with a fusion in which fusion is not detected.

  • Ewing-like sarcoma

  • Undifferentiated sarcoma

  • Inflammatory myofibroblastic tumor without ALK fusion

  • Infantile fibrosarcoma without NTRK fusion

  • Specimen Samples

    • Sufficient tumor specimen available to meet the minimum requirements for profiling from diagnosis or progression / recurrence

      --- OR

    • Surgery / biopsy planned as part of clinical care that is anticipated to yield sufficient material to meet the minimum requirements for profiling; OR

    • Patient has already had molecular profiling and patient has not yet started matched targeted therapy based on the report .

Exclusion Criteria:

  • No Therapy Planned

    -- Patients who have declined further anticancer therapy will be excluded.

  • Performance Status

    -- Patients with Lansky (age < 16 years) or Karnofsky (age ≥16 years) score < 50 will be excluded.

  • Life Expectancy -- Patients with anticipated life expectancy < 3 months will be excluded.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Genetic testing and GAIN report

All enrolled patients will submit specimens for sequencing and analysis.

All patients enrolled will submit specimens for genetic analysis. If successful the report will be reviewed to look for possible recommendations and a GAIN report will be generated regardless of possible recommendations.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Overall Survival
大体时间:18 months

In pediatric patients with recurrent or refractory solid tumors who undergo successful molecular profiling, a) to describe the overall survival of patients by treatment group (iCatM, iCatUM and UM); b) to identify demographic, clinical, and genomic factors associated with overall survival from the time of relapse/progression (OSr); and c)to store tumor material, derived cell lines / xenografts, and blood samples for general sample banking and potential future research.

18 months

次要结果测量

结果测量
大体时间
确定与 a) 有 iCat 推荐和 b) 接受匹配靶向治疗相关的患者、临床和药物获取因素。
大体时间:2年
2年
按治疗组确定与复发/难治性疾病和可测量/可评估疾病患者的反应和无进展生存时间相关的因素。
大体时间:2年
2年
描述儿科实体瘤在诊断和复发时分子变化的频率和范围,包括比较从复发和初始诊断中获得的成对肿瘤样本中的潜在靶向变异。
大体时间:2年
2年
确定参与基因组学研究是否提供心理健康,以及这是否与基因组理解水平和收到 iCat 推荐有关。
大体时间:2年
2年

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Katherine Janeway, MD、Dana-Farber Cancer Institute

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2015年10月1日

初级完成 (估计的)

2026年12月1日

研究完成 (估计的)

2026年12月1日

研究注册日期

首次提交

2015年6月18日

首先提交符合 QC 标准的

2015年8月7日

首次发布 (估计的)

2015年8月13日

研究记录更新

最后更新发布 (实际的)

2026年9月21日

上次提交的符合 QC 标准的更新

2026年9月17日

最后验证

2026年4月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

There is not plan to share IPD from this study at this time.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅